Biomarkers of Heterogeneity in Type 1 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

611 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-06-08

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Biomarkers of heterogeneity in type 1 diabetes: establishment of a biobank and an integrated approach to clinical and metabolic phenotyping of individuals with established T1DM. In this project the investigators are searching for biomarkers in 600 patients with established (\>5 years) diabetes. The inter-relation and patterns of expression in clinical, (auto)immune, metabolic, inflammatory and other parameters, and (potential) biomarkers are investogated. Blood and urine samples are collected annually (over 3 years) in standardized conditions and biobanked. In addition, 150 patients will undergo additional metabolic testing (such as mixed meal-tests).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes

NCT04164966

Type 1 Diabetes

ACTIVE_NOT_RECRUITING

Reproducibility of Glucose Fluctuations by Standardized Exercise for Patients With Type 1 Diabetes - a Method Study Based on Continuous Glucose Monitoring

NCT02942069

Diabetes Mellitus, Type 1 Exercise Continuous Glucose Monitoring

COMPLETED

Mechanisms of Type 1 Diabetes Endophenotypes

NCT05764850

Type 1 Diabetes Mellitus Genetic Predisposition to Disease

RECRUITING

Biomarkers in Exhaled Breath of Glucose Fluctuation in Type 1 Diabetes

NCT03435198

Volatile Organic Compounds Hypoglycemia Type 1 Diabetes Mellitus

COMPLETED

An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes

NCT01846312

Diabetes Diabetes Mellitus, Type 1

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Identifying biomarkers of type 1 diabetes heterogeneity can help to stage the disease, and identify risks such as the early development of damage and complications.

Type 1 diabetes has long been considered to be an autoimmune disease in which failure of immune tolerance induces a specific immune attack on insulin-producing beta-cells. Recent research shows that the pathophysiology of type 1 diabetes is heterogeneous, involving various beta-cell-specific processes, different genetic predispositions, and several disease stages. It is very important to recognize this heterogeneity as it results in an accumulation of differences in outcomes during the course of the disease.

This heterogeneity requires further elucidation as a heterogeneous disease is likely to require multiple approaches to stop or cure the pathophysiological pathways. This underscores the need for more biomarkers to identify this heterogeneity, the different phases of disease and the effects of interventions and cures.

In many countries and research groups, data and samples from newly-diagnosed individuals (i.e. within the first 6 months after diagnosis) have been collected and studied. Fewer data and samples are available from patients with longer disease duration. This prompted JDRF to grant a strategic research agreement (SRA) to Diabeter and UMC Groningen. Both clinics have access to a substantial clinical database since 1998 with medical record data of \> 3500 type 1 diabetes patients.

In this BIOMARKER project, the investigators intend to analyze hormonal, biochemical, immunological, inflammatory and psychological biomarkers of type 1 diabetes in patients with a disease duration of \> 5 years. A sample repository (serum, plasma, urine, DNA, RNA) is established which is also accessible to other interested collaborators.

The collection currently includes:

* Fasting samples (serum, plasma, urine, DNA, RNA) from 600 patients with type 1 diabetes (\> 5 years duration) taken annually at 3 timepoints
* Samples from 150 patients who underwent Mixed Meal Tolerance Tests (MMTT with 5 timepoints) at 2 occasions (1-year interval)
* Data from questionnaires on psychosocial burden, quality of life, neuropathy and hypoglycaemia completed by the patients
* Clinical datasets on their health, diabetes history, family history and clinical course during treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 1 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

600-cohort

Patients with long-term (\> 5 years) type 1 diabetes aged 16 years and older

As this is an observational study there is no intervention.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Type 1 diabetes determined by either autoantibodies or based on clinical and historical data or both
2. At least 5 years (1825 days) of type 1 diabetes
3. Minimum age 16 years
4. Treated for type 1 diabetes at a diabetes center participating in this study
5. Subject understands study protocol and agrees to comply with it and has been able to read the patient information sheet, has had time to ask questions and get answers and gives signed informed consent.

Exclusion Criteria

1. Non-type 1 diabetes
2. Patients with a duration of type 1 diabetes below 5 years
3. Patients under the age of 16 years
4. Pregnancy and breastfeeding, until 3 months (12 weeks) after childbirth or breastfeeding
5. On experimental medication or participating in other studies with conflicting goals and schedules
6. Diseases or conditions that the investigator/physician believes to be a contraindication to participate
7. Unwilling to be informed on incidental findings.

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No